Researchers explore earlier genetic diagnoses, improved cancer diagnostics, and genomic tracking of a deadly mpox outbreak in children. Studies demonstrate the potential to identify inherited conditions years before symptoms appear and improve childhood cancer testing.
Scientists identify chimeric RNA molecules as essential in cellular health and disease, finding they play a wide variety of critical roles in vital cellular processes. Faulty chimeric RNA are often malfunctioning in breast cancer tumors, prompting new cancer treatments targeting specific chimeras.
Researchers from Fondazione Telethon and TIGEM identified a novel biological mechanism for Lowe syndrome and demonstrated piclidenoson's effectiveness in correcting kidney cell function. The findings provide a promising new therapeutic strategy for this rare genetic disorder.
Researchers found that PSD-95 levels were elevated in mice with MEF2C haploinsufficiency, leading to cognitive impairments and seizures. Targeting PSD-95 may be effective in reducing seizures and rescuing cognitive abilities in those with MEF2C haploinsufficiency or other neurodevelopmental disorders.
A new study from Swansea University found that children with major congenital anomalies were less likely to achieve national academic standards, with socioeconomic deprivation having a more pronounced impact. The researchers highlight the need for integrated provision across health, education, and social services to support children wi...
A groundbreaking clinical case demonstrates precise liver-targeted base editing with no detectable off-target alterations. The therapy effectively converts the patient's homozygous genotype to a heterozygous state, holding immense therapeutic potential for hereditary liver disorders.
The study analyzed data from nearly 1 million individuals, revealing that everyone has around five million genetic variants, including 10,000 that alter gene sequences and 50 rare variants of uncertain clinical relevance. Most people would be categorized as at high risk of genetic risk for around three conditions, highlighting the impo...
The BabyMERIT trial will evaluate trametinib in infants with Noonan syndrome and related conditions who develop severe hypertrophic cardiomyopathy, a potentially life-threatening condition. The study aims to improve outcomes for these young patients by targeting a molecular pathway known to drive these disorders.
The grant will support Dr. Flanagan-Steet's research into understanding how metabolism and glycosylation work together during normal development and disease onset. The study aims to identify common biological pathways that contribute to rare diseases, with the ultimate goal of developing new treatments.
CURE SYNGAP1 launches a comprehensive Economic and Humanistic Burden Study on SYNGAP1-Related Disorders, examining the broader impact on patients, caregivers, and families. The study aims to provide data to support future discussions on therapy development and access, and to demonstrate the full burden of the condition.
Researchers at Aarhus University have demonstrated a new form of gene therapy that can correct genetic defects in patients' own stem cells. The technique, called prime editing, builds on CRISPR technology but works in a different way, inserting a small piece of correct DNA at the precise location of the defect. This method has signific...
Researchers at Children's Hospital of Philadelphia identified a genetic variant in the MAP2K4 gene associated with neurodevelopmental disorder symptoms such as developmental delay and epilepsy. The study revealed impaired JNK signaling in induced pluripotent stem cell-derived neurons, providing a potential therapeutic target for furthe...
Researchers at the University of California, Riverside, are testing a novel protein-based therapy to correct abnormal brain activity in Fragile X syndrome. The therapy, developed by Bowen's FX Therapeutics, aims to restore normal brain function in individuals with the disorder.
An international study found that variants in the IDUA gene, associated with mucopolysaccharidosis type I, can cause inherited retinal disease without broader health problems. The study highlights the importance of understanding how genetic variants affect the body, potentially leading to earlier recognition and treatment opportunities.
A study by the University of Osaka has identified shared disease mechanisms in lymphatic malformations, including the PI3K/AKT/mTOR pathway, and found that sirolimus, a drug targeting this pathway, is clinically effective across patients. The research also uncovered 10 additional disease-related molecules, including NFATC1, which may r...
A study has identified a molecular pathway controlling TFEB activity, revealing new druggable targets for therapies in rare genetic diseases, cancer, and disorders linked to lysosomal dysfunction. Lysosomal stress triggers TFEB activation, which boosts cellular recycling and adapts to stress.
A $7.6 million NIH grant will advance understanding of polyaminopathies, a group of rare genetic disorders affecting neurodevelopmental presentations. The grant will help identify new approaches to molecular diagnosis and care, as well as train the next generation of rare disease researchers.
A novel autologous gene therapy for Wiskott-Aldrich syndrome has demonstrated durable clinical benefits in a phase 3 study, with 96% survival at 1 and 5 years. The treatment, etu-cel, has also reduced severe infections and moderate-to-severe bleeding events.
A multi-center international study published in NEJM found that performing hematopoietic cell transplants shortly after detecting high-risk features in patients with Shwachman-Diamond Syndrome significantly improves survival rates. The study analyzed 847 cases and found that survival appeared to improve when early HCT treatment occurre...
A new study by UC Berkeley researchers suggests that hyperreactive astrocytes are a primary driver of childhood epilepsy, particularly in the inherited disorder tuberous sclerosis complex. The findings highlight possible therapies to reduce inflammation and alleviate seizures, challenging the traditional view that neurons are the sole ...
Researchers have made incremental progress in understanding hypermobile Ehlers-Danlos Syndrome, a genetic disorder characterized by unstable joints and chronic pain. Studies have revealed correlations between hormone levels and symptom severity, as well as the relationship between hypermobile individuals and sleep apnea.
Researchers identified a previously unrecognized form of inherited retinal degeneration caused by a specific EFEMP1 gene variant, primarily affecting peripheral retina and rod photoreceptors. The disease can begin before visible retinal damage and may go undetected for a considerable period due to relatively preserved central vision.
Researchers at the University of Toronto have developed a next-generation RNA therapeutic approach that can treat a wide range of genetic diseases by helping cells read through premature stop signals. The approach, centered on transfer RNA, has shown promise in laboratory and preclinical models of cystic fibrosis, and may be combined w...
Researchers developed a genetic risk score to analyze risk of type 1 diabetes in patients with MODY, identifying 16% with atypical type 1 diabetes. The score, now adopted as part of NHS testing, provides a diagnosis for patients with negative MODY tests.
Researchers have developed a machine learning model that can help clinicians assess uncertain variants in prenatal genetic testing, providing more accurate diagnoses and clearer information for families. The approach uses tissue-agnostic episignatures to overcome limitations in epigenetic testing.
A new review highlights how molecular biology advances are reframing PAH as a complex vascular remodeling disease driven by endothelial dysfunction, chronic inflammation, metabolic dysregulation, and genetic susceptibility. Emerging therapies target the BMP/TGF-β pathway, growth factor signaling, and inflammatory pathways.
Katherine Wilemon, Family Heart Foundation CEO, receives Honorary Fellow Award from ASPC for her advocacy and research efforts in inherited lipid disorders. The award reflects the organization's impact on advancing care and awareness for conditions like familial hypercholesterolemia.
A study by Dawood Darbar and colleagues found that rare genetic mutations converge with common genetic variants to disrupt the heart's electrical activity, leading to early-onset atrial fibrillation. This additive effect amplifies the risk of stroke and other cardiovascular complications.
Researchers discovered a small mutation in the RBM20 protein leads to vastly different disorders in heart muscle cells. The study identified molecular targets for patient-specific therapies and potential new active substances.
A phase 3 trial found that deramiocel, a heart-derived cellular therapy, slowed muscle weakening and preserved heart function in boys and young men with advanced Duchenne muscular dystrophy. The therapy also showed promise in reducing scarring in the heart.
New national standards recommend earlier screening and lifelong monitoring for development and cognition in individuals with SCD, aiming to reduce variability in care. The guidance, developed in collaboration with Children's Colorado, provides a tiered approach to care, including surveillance and evaluation.
The IOF Musculoskeletal Rare Diseases Training Course bridges latest scientific advances with current clinical guidance, covering disorders-specific programs. Clinicians can access high-quality educational content at their own pace to deepen expertise in rare skeletal conditions diagnosis and management.
A new study published in the Journal of Inherited Metabolic Disease found that high-dose niacin therapy can improve survival outcomes in children with NAXD deficiency, a rare genetic disorder. The treatment has been shown to halt significant deterioration and reduce life-threatening complications.
Scientists have discovered a new approach to treating genetic brain disorders by redirecting brain development. The therapy helps at-risk neurons grow and connect more normally, strengthening connections among existing neurons and restoring cognitive function.
A study on La Brea Tar Pits fossils found rare spinal nerve tumors and developmental abnormalities, suggesting a dwindling species was in poor genetic health. This may have made them more vulnerable to hunting, ultimately contributing to their extinction.
Researchers at the University of Colorado Anschutz Linda Crnic Institute discovered unique biological processes altered among individuals with Down syndrome who have different sets of co-occurring conditions. The findings mark an important step toward personalized treatment, enabling future targeted therapies and improved health outcomes.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
Researchers found subtle patterns in brain activity while children listened to speech linked to verbal communication abilities in autistic youths. Altered brain signals suggested the brain may process speech less efficiently, with noisier signals associated with lower scores on everyday verbal communication.
Researchers analyzed genetic data from almost 100,000 people across eleven world regions, identifying regional differences in gene variants GBA1 and LRRK2. This study is crucial for globally equitable diagnostics and therapies as it highlights the need to consider ancestry when diagnosing Parkinson's disease.
The study demonstrated sustained improvements in disease features in mouse models with effects lasting throughout their lifespan. Genespire's approach has the potential to translate into human health as a single-administration treatment for patients with MMA.
A USC interdisciplinary team has identified a promising pathway to turn off brain inflammation before it does its damage, increasing the risk of late-onset Alzheimer's. The Norman and Mary Pattiz Foundation funding will support research on novel drug discovery, early detection, and prevention of Alzheimer's disease.
Researchers found that Down syndrome is associated with low saliva production and gum disease due to calcium signaling dysfunction and changes in the oral microbiome. The study suggests that addressing underlying biological factors and improving oral hygiene may help alleviate these issues.
The study reveals how genetic mutations disrupt muscle signaling in CMS, a family of genetic disorders that weaken communication between nerves and muscles. Researchers identified promising new therapeutic opportunities, including a potential use for an existing antidepressant.
Researchers developed zebrafish model that reproduces key features of CADASIL, a hereditary disease causing brain damage and recurrent strokes. The study found progressive decline in cerebral blood flow and impaired learning ability, similar to human patients.
Researchers developed a gene therapy that restored normal brain activity and improved behavior in mice with Fragile X syndrome by replacing the missing FMRP protein. The treatment administered during early development showed significant improvements in cognitive flexibility, social interactions, and probabilistic reversal learning.
A team studied 173 multiplex families from the Azores and Madeira islands, finding a single broken gene that travels through three generations and causes different illnesses. The CHD2 mutation is rare and affects schizophrenia, mood disorder, and autism in different family members.
Researchers emphasize the need for large-scale population studies to assess the risks of newborn genome screening and minimize overdiagnosis. The study highlights that most genetic research has been conducted in individuals with a condition or high-risk family, resulting in underestimated risk estimates.
A study has identified a genetic cause for pediatric-onset pyoderma gangrenosum, a rare inflammatory skin condition. The researchers discovered that a mutation in the OTULIN gene leads to the condition, which is characterized by recurrent ulcerating skin sores.
Researchers have found a potential new treatment for DHDDS-related disease by creating mini-brains from patients' cells and testing vitamin B3. The study showed significant improvements in patients' symptoms, including reduced tremors and increased energy levels.
A new DNA test offers a much more complete picture of DNA than current standard diagnostics, leading to a diagnosis more often. The test can replace fifteen other tests, making it faster and more efficient for rare genetic disorders.
Researchers describe a novel disorder caused by biallelic loss-of-function variants in the TMEM63B gene, resulting in severe lung disease. The disorder presents with early onset respiratory distress, lung abnormalities, and developmental delay but no epilepsy.
A pediatric ophthalmologist is leading a $1 million NIH grant to study the genetics of cataracts in children. The goal is to develop a comprehensive AI-assisted database of genes associated with potential diseases.
A team of researchers has made a significant contribution to understanding human genetics by mapping the Japanese genome, revealing new insights into genetic disease shaping in the Japanese population. The study nearly doubled the complete reconstruction rate to 91.2%, enabling better personalized medicine and treatment options.
The JTMF Foundation has expanded its footprint with a $3.3 million gift to fund three main initiatives: identifying early signs of Alzheimer's in adults with Down syndrome, expanding access to cutting-edge clinical research, and developing best-practice guidelines.
A new EPI-SLEEP study will investigate the impact of personalized in-ear sleep technology on sleep disturbances and circadian health in adults with epilepsy. The study aims to generate robust evidence for a low-risk approach to improving sleep without adding medication burden.
The HUG-CELL project aims to identify couples at risk of transmitting recessive genetic disorders and Fragile X syndrome. The initiative will create a large genetic database for Brazil to determine the prevalence of hereditary genetic diseases and develop 'risk calculators' based on the diversity of the Brazilian population.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
Researchers will investigate the link between SYNGAP1 protein deficiency, cilia dysfunction, and clinical symptoms of SYNGAP1-Related Disorders. The study aims to inform rational drug design and provide new insights for targeted therapies.
CURE SYNGAP1 invests in remote assessment tools to broaden access to clinical care and trials for patients with SYNGAP1-Related Disorders. The study aims to evaluate the validity of a standardized remote developmental assessment to reduce travel burden.
The CURE SYNGAP1 COLLECTIVE is a collaborative framework uniting independent SYNGAP1 charities worldwide to accelerate treatments for individuals with SYNGAP1-Related Disorders. The Collective focuses on three primary pillars: research, industry engagement, and patient advocacy.